<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01087645</url>
  </required_header>
  <id_info>
    <org_study_id>NN9925-3779</org_study_id>
    <secondary_id>2009-016975-31</secondary_id>
    <secondary_id>U1111-1113-2537</secondary_id>
    <nct_id>NCT01087645</nct_id>
  </id_info>
  <brief_title>A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects</brief_title>
  <official_title>Investigation of Safety, Tolerability and Bioavailability of NN9925 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate the safety,
      tolerability and bioavailability (exploring absorption of drug in body) of NN9925 in healthy
      male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2010</start_date>
  <completion_date type="Actual">September 16, 2010</completion_date>
  <primary_completion_date type="Actual">September 16, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of adverse events (AEs) recorded</measure>
    <time_frame>from dosing to Day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The uptake in blood of oral NN9925</measure>
    <time_frame>from 0 to 504 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Trial part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trial part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NN9925 (oral)</intervention_name>
    <description>Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation</description>
    <arm_group_label>Trial part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NN9925 (i.v.)</intervention_name>
    <description>As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit</description>
    <arm_group_label>Trial part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels</description>
    <arm_group_label>Trial part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NN9925 (oral)</intervention_name>
    <description>Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1</description>
    <arm_group_label>Trial part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects will be randomised to receive a single dose of placebo</description>
    <arm_group_label>Trial part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects with good general health as judged by the physician

          -  Body weight of 65-95 kg (both inclusive)

          -  Body Mass Index (BMI) of 18.5-27.5 kg/m2 (both inclusive)

        Exclusion Criteria:

          -  Known or suspected allergy to trial product or related products

          -  Acute infection or inflammation or other illness that may confound the results of the
             trial or pose a risk to the subject by administering the trial product, as judged by
             the physician

          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,
             vomiting, heartburn or diarrhoea) or malabsorptive states of disease (celiac disease,
             lactose intolerance or chronic pancreatitis), as judged by the physician
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2010</study_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

